Floatz logo

HM15211 (LONG-ACTING GLP-1/GIP/GLUCAGON TRIPLE AGONIST)

NAFLD

Hanmi Pharmaceutical Company Limitedprotein_peptidePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

140 Active assets in the NAFLD cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

HM15211 (LONG-ACTING GLP-1/GIP/GLUCAGON TRIPLE AGONIST) is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
53 / 100
View asset →
obesity disorderDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →